INSM
Insmed Incorporated
October 5, 2026 · pre-market
- Rarity
- 1.76
- Peak move
- −8.42%
- Float cap
- $23.4B
Insmed Incorporated is a global biopharmaceutical company that develops and commercializes therapies for patients with serious diseases. Its commercial products are ARIKAYCE for MAC lung disease and BRINSUPRI for non-cystic fibrosis bronchiectasis. Its pipeline spans respiratory, immunology and inflammation, and neuro and other rare diseases.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
2 events · 2 from SEC or newswire · 2 timed with the move- Timed with the move
ceo_cfo_departureInsmed announced CFO Sara Bonstein will separate from the company effective October 30, 2026, after nearly seven years in the role, with a successor search underway and the separation not related to any disagreement over accounting, financial statements, internal controls or operations; the company reaffirmed full-year 2026 guidance and set its Q3 2026 results call for October 29, 2026.
SEC8-K 0001140361-26-038529wireprnewswire.com - Timed with the move
guidance_changeInsmed provided guidance information for the third quarter of 2026 in a press release issued October 5, 2026, disclosed under Item 7.01, alongside the announcement of CFO Sara Bonstein's separation.
SEC8-K 0001140361-26-038529